Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

169.91USD
17 May 2019
Change (% chg)

$-0.01 (-0.01%)
Prev Close
$169.92
Open
$169.27
Day's High
$171.24
Day's Low
$169.11
Volume
2,266,628
Avg. Vol
3,022,640
52-wk High
$210.19
52-wk Low
$166.30

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.90 29.30 32.55
EPS (TTM): 11.00 -- --
ROI: 11.98 14.23 13.82
ROE: 26.43 15.46 15.24

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.

May 10 2019

UPDATE 1-Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS, May 10 Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of fi

May 10 2019

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS, May 10 Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of fi

May 10 2019

Amgen revenue flat as migraine, cholesterol drugs miss sales expectations

Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.

Apr 30 2019

UPDATE 2-Amgen revenue flat as migraine, cholesterol drugs miss sales expectations

April 30 Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.

Apr 30 2019

Amgen revenue flat for first quarter, Aimovig, Repatha fall short of sales expectations

April 30 Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago and net income fell 14 percent as sales of key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face competition and pressure to lower prices.

Apr 30 2019

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

BOSTON Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

Apr 25 2019

UPDATE 3-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

Apr 25 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Apr 25 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Apr 25 2019

Earnings vs. Estimates